Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 40 mg/0.4ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - uveitis humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 20 mg/0.2ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 80 mg/0.8ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 80 mg/0.8ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - adalimumab -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - adalimumab -

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - adalimumabum - solution injectable en stylo prérempli - lösung: adalimumabum 40 mg, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. tela cum: alcohol isopropylicus et aqua purificata. - la polyarthrite rhumatoïde, le plus tôt diagnostiqué une polyarthrite rhumatoïde, de rhumatisme psoriasique, de spondylarthrite ankylosante (maladie de bechterew), la maladie de crohn, le psoriasis en plaques, la colite ulcéreuse, l'arthrite juvénile idiopathique polyarticulaire, hidrosadénite suppurée, une uvéite - biotechnologika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - adalimumabum - solution injectable en stylo prérempli - lösung: adalimumabum 80 mg, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. tela cum: alcohol isopropylicus et aqua purificata. - la polyarthrite rhumatoïde, le plus tôt diagnostiqué une polyarthrite rhumatoïde, de rhumatisme psoriasique, de spondylarthrite ankylosante (maladie de bechterew), la maladie de crohn, le psoriasis en plaques, la colite ulcéreuse, l'arthrite juvénile idiopathique polyarticulaire, hidrosadénite suppurée, une uvéite - biotechnologika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - adalimumabum - solution injectable dans une seringue préremplie - lösung: adalimumabum 40 mg, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. tela cum: alcohol isopropylicus et aqua purificata. - la polyarthrite rhumatoïde, le plus tôt diagnostiqué une polyarthrite rhumatoïde, de rhumatisme psoriasique, de spondylarthrite ankylosante (maladie de bechterew), la maladie de crohn, le psoriasis en plaques, la colite ulcéreuse, l'arthrite juvénile idiopathique polyarticulaire, hidrosadénite suppurée, une uvéite - biotechnologika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - adalimumabum - solution injectable en flacon - lösung: adalimumabum 40 mg, mannitolum, l'acide citricum monohydricum, natrii citras dihydricus, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, natrii chloridum, polysorbatum 80, eau pour iniectabilia q.s. pour une solution au lieu de 0,8 ml. web avec: l'alcool isopropylicus et aqua purificata. - arthrite l'arthrite juvénile à partir de 4 ans; la maladie de crohn chez les enfants et les jeunes à partir de 6 ans; le psoriasis en plaques chez les enfants et les jeunes à partir de 6 ans - biotechnologika